Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Ингибитор ангиотензинпревращающего фермента периндоприл в лечении пациентов с артериальной гипертензией - Журнал Системные Гипертензии Том 11, №3
Ингибитор ангиотензинпревращающего фермента периндоприл в лечении пациентов с артериальной гипертензией
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Согласно рекомендациям European Society of Hypertension 2013 г. лечение артериальной гипертензии возможно любой из известных групп антигипертензивных препаратов. При этом нередко приходится прибегать к разным комбинациям препаратов. В данной ситуации комбинация препаратов в фиксированной дозе значительно облегчает задачу и увеличивает приверженность пациентов лечению. Результаты многочисленных исследований показали, что периндоприл достоверно снижает общую и сердечно-сосудистую смертность, а также частоту развития инфаркта миокарда, а комбинация его с антагонистом кальция делает препарат еще более эффективным.
Ключевые слова: артериальная гипертензия, периндоприл, Престариум, Престанс, ASCOT, EUROPA, PROGRESS, STRONG, SYMBIO, PERSPECTIVA.
Key words: arterial hypertension, perindopril, Prestarium, Prestance, ASCOT, EUROPA, PROGRESS, STRONG, SYMBIO, PERSPECTIVA.
Ключевые слова: артериальная гипертензия, периндоприл, Престариум, Престанс, ASCOT, EUROPA, PROGRESS, STRONG, SYMBIO, PERSPECTIVA.
________________________________________________
Key words: arterial hypertension, perindopril, Prestarium, Prestance, ASCOT, EUROPA, PROGRESS, STRONG, SYMBIO, PERSPECTIVA.
Полный текст
Список литературы
1. Sever PS, Dahlof B, Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 6: 1139–47.
2. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT–BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
3. Poulter NP, Sever PS. Anglo-Scandinavian Cardiac Outcomes Trial. Caric Print Limited 2005; 108.
4. Sever PS, Dahlof B, Poulter NR et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT–BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
5. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than–average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT–LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
6. EURopean trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
7. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
8. The CAFÉ investigators, for the ASCOT investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
9. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
10. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.
11. Poulter NR, Sever PS, Dahlof B, Wedel H. ASCOT sub-studes. Anglo-Scandinavian Cardiac Outcomes Trial. Latest perspectives on this landmark trial. 3d ed. Sherborne Gibbs 2011: 35–45.
12. Rothwell PM, Howard SC, Dolan E et al on behalf of the ASCOTBPLA and MRC Trial Investigators. Effects of b-blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469–80.
13. Hatala R, Bachanov K, Sidio R. SYMBIO: results of a longitudinal study of optimized blood pressurelowering therapy with fixed combination perindopril/amlodipine. Abstracts of 20 th European hypertension society meeting. Oslo, 2010.
14. Bangalore S, Kamalakkannan G, Parkar S et al. Fixeddose combinations improve medication compliance: a metaanalysis. Am J Med 2007; 120: 713–9.
15. Drambyan M, Fljyan N, Makaryan Yu, TerMargaryan A. The influence of Prestans 10/5 (prestarium + amlodipine) on arterial hypertension and heart rate variability in elderly patients with isolated systolic hypertension. Abstracts of 20th European hypertension society. Oslo, 2010.
16. Dolan EA, Stanton AVB, Parker KH et al on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – ASCOT substudy. J Hypertens 2009; 27: 876–85.
2. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT–BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
3. Poulter NP, Sever PS. Anglo-Scandinavian Cardiac Outcomes Trial. Caric Print Limited 2005; 108.
4. Sever PS, Dahlof B, Poulter NR et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT–BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
5. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than–average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT–LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
6. EURopean trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
7. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
8. The CAFÉ investigators, for the ASCOT investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
9. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
10. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.
11. Poulter NR, Sever PS, Dahlof B, Wedel H. ASCOT sub-studes. Anglo-Scandinavian Cardiac Outcomes Trial. Latest perspectives on this landmark trial. 3d ed. Sherborne Gibbs 2011: 35–45.
12. Rothwell PM, Howard SC, Dolan E et al on behalf of the ASCOTBPLA and MRC Trial Investigators. Effects of b-blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469–80.
13. Hatala R, Bachanov K, Sidio R. SYMBIO: results of a longitudinal study of optimized blood pressurelowering therapy with fixed combination perindopril/amlodipine. Abstracts of 20 th European hypertension society meeting. Oslo, 2010.
14. Bangalore S, Kamalakkannan G, Parkar S et al. Fixeddose combinations improve medication compliance: a metaanalysis. Am J Med 2007; 120: 713–9.
15. Drambyan M, Fljyan N, Makaryan Yu, TerMargaryan A. The influence of Prestans 10/5 (prestarium + amlodipine) on arterial hypertension and heart rate variability in elderly patients with isolated systolic hypertension. Abstracts of 20th European hypertension society. Oslo, 2010.
16. Dolan EA, Stanton AVB, Parker KH et al on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – ASCOT substudy. J Hypertens 2009; 27: 876–85.
2. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT–BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
3. Poulter NP, Sever PS. Anglo-Scandinavian Cardiac Outcomes Trial. Caric Print Limited 2005; 108.
4. Sever PS, Dahlof B, Poulter NR et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT–BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
5. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than–average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT–LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
6. EURopean trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
7. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
8. The CAFÉ investigators, for the ASCOT investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
9. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
10. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.
11. Poulter NR, Sever PS, Dahlof B, Wedel H. ASCOT sub-studes. Anglo-Scandinavian Cardiac Outcomes Trial. Latest perspectives on this landmark trial. 3d ed. Sherborne Gibbs 2011: 35–45.
12. Rothwell PM, Howard SC, Dolan E et al on behalf of the ASCOTBPLA and MRC Trial Investigators. Effects of b-blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469–80.
13. Hatala R, Bachanov K, Sidio R. SYMBIO: results of a longitudinal study of optimized blood pressurelowering therapy with fixed combination perindopril/amlodipine. Abstracts of 20 th European hypertension society meeting. Oslo, 2010.
14. Bangalore S, Kamalakkannan G, Parkar S et al. Fixeddose combinations improve medication compliance: a metaanalysis. Am J Med 2007; 120: 713–9.
15. Drambyan M, Fljyan N, Makaryan Yu, TerMargaryan A. The influence of Prestans 10/5 (prestarium + amlodipine) on arterial hypertension and heart rate variability in elderly patients with isolated systolic hypertension. Abstracts of 20th European hypertension society. Oslo, 2010.
16. Dolan EA, Stanton AVB, Parker KH et al on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – ASCOT substudy. J Hypertens 2009; 27: 876–85.
________________________________________________
2. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT–BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
3. Poulter NP, Sever PS. Anglo-Scandinavian Cardiac Outcomes Trial. Caric Print Limited 2005; 108.
4. Sever PS, Dahlof B, Poulter NR et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT–BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
5. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than–average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT–LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
6. EURopean trial. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
7. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
8. The CAFÉ investigators, for the ASCOT investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
9. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
10. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.
11. Poulter NR, Sever PS, Dahlof B, Wedel H. ASCOT sub-studes. Anglo-Scandinavian Cardiac Outcomes Trial. Latest perspectives on this landmark trial. 3d ed. Sherborne Gibbs 2011: 35–45.
12. Rothwell PM, Howard SC, Dolan E et al on behalf of the ASCOTBPLA and MRC Trial Investigators. Effects of b-blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469–80.
13. Hatala R, Bachanov K, Sidio R. SYMBIO: results of a longitudinal study of optimized blood pressurelowering therapy with fixed combination perindopril/amlodipine. Abstracts of 20 th European hypertension society meeting. Oslo, 2010.
14. Bangalore S, Kamalakkannan G, Parkar S et al. Fixeddose combinations improve medication compliance: a metaanalysis. Am J Med 2007; 120: 713–9.
15. Drambyan M, Fljyan N, Makaryan Yu, TerMargaryan A. The influence of Prestans 10/5 (prestarium + amlodipine) on arterial hypertension and heart rate variability in elderly patients with isolated systolic hypertension. Abstracts of 20th European hypertension society. Oslo, 2010.
16. Dolan EA, Stanton AVB, Parker KH et al on behalh of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – ASCOT substudy. J Hypertens 2009; 27: 876–85.
Авторы
А.И.Мартынов, И.В.Урлаева, Е.В.Акатова, О.П.Николин
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.